Asthma: Still a promising future?

European Respiratory Review

Volumn 23, Issue 134, 2014, Pages 405-407

  Chanez, Pascal ^a   Humbert, Marc ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; ANTIASTHMATIC AGENT;

ADAPTIVE IMMUNITY; ASTHMA; BRONCHIAL THERMOPLASTY DEVICE; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DENDRITIC CELL; DISEASE EXACERBATION; EDITORIAL; ENVIRONMENTAL EXPOSURE; EOSINOPHIL; EPIGENETICS; HUMAN; HYGIENE; IMMUNOTHERAPY; INNATE IMMUNITY; LIFESTYLE; MEDIATOR RELEASE; RESPIRATORY TRACT INFLAMMATION; RISK FACTOR; IMMUNOLOGY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSIOLOGY; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANTI-ASTHMATIC AGENTS; ASTHMA; CYTOKINES; HUMANS; IMMUNITY, INNATE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 84914177602     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00009614     Document Type: Editorial

References (14)

1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
2. Bourdin A, Molinari N, Vachier I, et al. Prognostic value of cluster analysis of severe asthma phenotypes. J Allergy Clin Immunol 2014 [In press DOI: 10.1016/j.jaci.2014.04.038].
3. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
4. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
5. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224-1233.
6. Garcia G, Taillé C, Laveneziana P, et al. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 2013; 22: 251-257.
7. Gras D, Chanez P, Vachier I, et al. Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther 2013; 140: 290-305.
8. Barnig C, Cernadas M, Dutile S, et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 2013; 5: 174ra26.
9. Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J 2014; 44: 239-241.
10. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207.
11. Moss RB. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J 2014; 43: 1487-1500.
12. Iyer VN, Lim KG. Bronchial thermoplasty: reappraising the evidence (or lack thereof). Chest 2014; 146: 17-21.
13. Sheshadri A, Castro M, Chen A. Bronchial thermoplasty: a novel therapy for severe asthma. Clin Chest Med 2013; 34: 437-444.
14. Dombret M-C, Alagha K, Boulet LP, et al. Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults. Eur Respir Rev 2014; 23: 510-518.